Investigating how SGLT2 inhibitors can help treat fatty liver disease in children
Mechanisms of SGLT2 Inhibition in Pediatric NAFLD
This study is looking at how a type of medication called SGLT2 inhibitors can help reduce liver fat in children with nonalcoholic fatty liver disease, especially those who are overweight or have insulin resistance, to find better treatment options for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lurie Children's Hospital of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11039933 on NIH RePORTER |
What this research studies
This research focuses on nonalcoholic fatty liver disease (NAFLD), which is the most common liver disease in children and often linked to obesity and insulin resistance. The study aims to explore the effects of sodium glucose co-transporter-2 inhibitors (SGLT2i) on reducing liver fat in pediatric patients who are not yet diabetic. By examining how these medications can improve liver health and metabolic function, the research seeks to provide new treatment options for affected children. The approach includes assessing changes in liver fat and metabolic markers in a controlled clinical setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and adolescents aged 2 to 19 years who are diagnosed with nonalcoholic fatty liver disease and exhibit signs of obesity or insulin resistance.
Not a fit: Patients who are not diagnosed with nonalcoholic fatty liver disease or those who have already developed type 2 diabetes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective pharmacotherapy options for children suffering from NAFLD, improving their liver health and overall quality of life.
How similar studies have performed: Previous research has shown promising results with SGLT2 inhibitors in adults, but this approach in the pediatric population is novel and has not yet been extensively tested.
Where this research is happening
Chicago, United States
- Lurie Children's Hospital of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Ryder, Justin R. — Lurie Children's Hospital of Chicago
- Study coordinator: Ryder, Justin R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.